Imfinzi combination snags FDA approval for high-risk non-muscle invasive bladder cancer

medpagetoday.com·May 28, 2026 · 1 g fa

FDA OKs Immunotherapy-BCG Combo for High-Risk Bladder Cancer

morningstar.com·May 29, 2026 · 1 g fa

IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer

fiercepharma.com·May 28, 2026 · 1 g fa

AstraZeneca gains 2nd bladder cancer nod in key expansion for Imfinzi

medpagetoday.com·May 26, 2026 · 3 g fa

New First-Line Option Approved in Triple-Negative Breast Cancer

pharmaceutical-technology.com·May 28, 2026 · 1 g fa

FDA oncology roundup: AbbVie’s rare cancer approval, AstraZeneca in breast cancer limbo - Pharmaceutical Technology

endpoints.news·May 29, 2026 · 16 h fa

AstraZeneca seeks path for failed antibody; Imfinzi, Tremfya get label expansions

morningstar.com·May 28, 2026 · 2 g fa

U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options

endpoints.news·May 28, 2026 · 1 g fa

AbbVie clinches FDA approval for ultra-rare blood cancer ADC from ImmunoGen purchase

pharmaceutical-technology.com·May 25, 2026 · 4 g fa

AstraZeneca, Daiichi Sankyo's Datroway receives FDA approval for TNBC

medpagetoday.com·May 27, 2026 · 2 g fa

Decnupaz Approved for Rare Blood Cancer